| Registro completo |
| Provedor de dados: |
BJMBR
|
| País: |
Brazil
|
| Título: |
High levels of LDL-C combined with low levels of HDL-C further increase platelet activation in hypercholesterolemic patients
|
| Autores: |
Chan,L.W.
Luo,X.P.
Ni,H.C.
Shi,H.M.
Liu,L.
Wen,Z.C.
Gu,X.Y.
Qiao,J.
Li,J.
|
| Data: |
2015-02-01
|
| Ano: |
2015
|
| Palavras-chave: |
Low-density lipoprotein cholesterol
High-density lipoprotein cholesterol
Platelet activation
Statins
PAC-1
CD62p
|
| Resumo: |
High levels of low-density lipoprotein cholesterol (LDL-C) enhance platelet activation, whereas high levels of high-density lipoprotein cholesterol (HDL-C) exert a cardioprotective effect. However, the effects on platelet activation of high levels of LDL-C combined with low levels of HDL-C (HLC) have not yet been reported. We aimed to evaluate the platelet activation marker of HLC patients and investigate the antiplatelet effect of atorvastatin on this population. Forty-eight patients with high levels of LDL-C were enrolled. Among these, 23 had HLC and the other 25 had high levels of LDL-C combined with normal levels of HDL-C (HNC). A total of 35 normocholesterolemic (NOMC) volunteers were included as controls. Whole blood flow cytometry and platelet aggregation measurements were performed on all participants to detect the following platelet activation markers: CD62p (P-selectin), PAC-1 (GPIIb/IIIa), and maximal platelet aggregation (MPAG). A daily dose of 20 mg atorvastatin was administered to patients with high levels of LDL-C, and the above assessments were obtained at baseline and after 1 and 2 months of treatment. The expression of platelets CD62p and PAC-1 was increased in HNC patients compared to NOMC volunteers (P<0.01 and P<0.05). Furthermore, the surface expression of platelets CD62p and PAC-1 was greater among HLC patients than among HNC patients (P<0.01 and P<0.05). Although the expression of CD62p and PAC-1 decreased significantly after atorvastatin treatment, it remained higher in the HLC group than in the HNC group (P<0.05 and P=0.116). The reduction of HDL-C further increased platelet activation in patients with high levels of LDL-C. Platelet activation remained higher among HLC patients regardless of atorvastatin treatment.
|
| Tipo: |
Info:eu-repo/semantics/article
|
| Idioma: |
Inglês
|
| Identificador: |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2015000200167
|
| Editor: |
Associação Brasileira de Divulgação Científica
|
| Relação: |
10.1590/1414-431x20144182
|
| Formato: |
text/html
|
| Fonte: |
Brazilian Journal of Medical and Biological Research v.48 n.2 2015
|
| Direitos: |
info:eu-repo/semantics/openAccess
|
